Pfizer inks genetic license with Genizon

Pfizer has licensed the diagnostic rights involved in the genetic research of Genizon BioSciences in Alzheimer's, ADHD, and endometriosis. Pfizer is providing an unspecified upfront fee, research money and an equity investment. Genizon is retaining the therapeutic rights associated with its research on the Quebec Founder Population, which is being used to develop genetic markers to predict the risk of disease.

"We are excited about the broad scope and combined contributions of this collaboration," said Dr. John W. Hooper, president and CEO of Genizon. "We expect the results of this research to lead to earlier and more accurate diagnosis and improved health care for patients afflicted with Alzheimer's disease, ADHD and endometriosis."

- check out the release on Pfizer's pact

Related Articles:
Archemix and Pfizer forge discovery pact. Report
Scripps inks $100M research pact with Pfizer. Report
Pfizer strikes deal for UK's PowderMed. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.